Celebrating another Victory for Mental Health Treatment
We are proud to announce that Premier Clinical Research, Inc has played a vital role in the development of a groundbreaking treatment for schizophrenia. The most widely used atypical antipsychotic is now available as a once-monthly injection, following its recent approval by the US Food and Drug Administration (FDA).
Teva’s olanzapine, a trusted treatment for schizophrenia for decades, is now offered as an extended-release injectable suspension under the brand name Weltruza. This innovative once-monthly subcutaneous injection is set to transform the way patients manage their condition. Teva will provide Weltruza in three doses: 318mg, 425mg, and 531mg. Importantly, it does not require loading doses, oral supplementation, or post-injection monitoring, making it a convenient option for so many patients.
-Innovative Technology for Better Adherence-
The oral version of olanzapine has been a cornerstone in treating schizophrenia since its approval in 1996. As the most widely prescribed atypical antipsychotic, it has provided significant relief to countless people. Weltruza's formulation is designed to enhance long-term symptom improvement by addressing the challenges of adherence associated with daily oral medications. Many patients struggle with daily medication, and this new option aims to alleviate that burden.
Our site was contributor in the Phase III SOLARIS trial (NCT05693935) which helped get this approved and able to be prescribed. We are excited to see how this new injectable can further enhance patient outcomes and are so proud of our team for putting in the work.
As we celebrate this significant advancement in schizophrenia treatment, we extend our gratitude to all of the participants who contributed to this journey at our site and throughout the study. Together, we are making strides toward better mental health care and improved quality of life for those living with schizophrenia. Moments like these are what remind us of why we do what we do, and how important clinical research is.
Comments